← Metformin × all-cause mortality

SynthesisMedicine2020

Relationships are between metformin use and survival in pancreatic cancer patients concurrent with diabetes: A systematic review and meta-analysis.

Yu-Qi Shi et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 38,772 people · 2020

Not counted

Reduced deaths

−17%−26% to −9%

Bigger than 5 in 10 for all-cause mortality

As reported

HR 0.83, 95% CI 0.74–0.91 · the paper's word: All-cause mortality

Not counted

Reduced deaths

−18%−31% to −6%

Bigger than 5 in 10 for all-cause mortality

As reported

HR 0.82, 95% CI 0.69–0.94 · the paper's word: All-cause mortality

Not counted

Reduced deaths

−15%−23% to −7%

Bigger than 5 in 10 for all-cause mortality

As reported

HR 0.85, 95% CI 0.77–0.93 · the paper's word: All-cause mortality

Range includes no effect

No clear effect on deaths

−1%−33% to +30%

Smaller than almost all for all-cause mortality

As reported

HR 0.99, 95% CI 0.67–1.30 · the paper's word: All-cause mortality

Four numbers in the abstract

the abstract, start to end

… non-metformin group (hazard ratio [HR] = 0.83, 95% confidence interval [CI]: …

… in patients receiving surgery (HR = 0.82, 95% CI: 0.69-0.94) and comprehensive treatment (HR = 0.85, 95% CI: 0.77-0.93), but not in chemotherapy group (HR = 0.99, 95% CI: 0.67-1.30).

← favours treatmentfavours comparator →
could be chance
All-cause mortality
HR 0.830.74–0.91
All-cause mortality
HR 0.820.69–0.94
All-cause mortality
HR 0.850.77–0.93
All-cause mortality
HR 0.990.67–1.30
MetforminAll-cause mortality
1 / 3

34 papers cite it

2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 32925714